Skip to search formSkip to main contentSkip to account menu

darusentan

Known as: (+)-(S)-2-((4,6-dimethoxy-2-pyrimidinyl)oxy)-3-methoxy-3,3-diphenylpropionic acid, benzenepropanoic acid, alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-, (S)- 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Patients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing… 
Highly Cited
2010
Highly Cited
2010
To evaluate potential mechanisms of clinical hepatotoxicity, 4 endothelin receptor antagonists (ERAs) were examined for substrate… 
Review
2010
Review
2010
Resistant hypertension is commonly found in everyday clinical practice. However, the risks of resistant hypertension, as well as… 
Highly Cited
2007
Highly Cited
2007
In this phase 2, randomized, double‐blind, placebo‐controlled forced dose‐titration study, 115 patients with resistant… 
Review
2006
Review
2006
Since its initial characterization in 1988, over 18,236 papers, including 2,485 reviews, have been published in the endothelin… 
Highly Cited
2002
Highly Cited
2002
Background—The endothelin (ET-1) system is activated in chronic heart failure (CHF). Whether, what type, and what degree of… 
Highly Cited
2002
Highly Cited
2002